BCL2 and prostate carcinoma: Several studies have linked overexpression of the antiapoptosis protein bcl-2 with decreased expression of the proapoptotic protein bax, and adverse outcomes in prostate cancer are associated with resistance to cytotoxic chemotherapy in patients with hormone-refractory disease [285,286].